

Patient characteristics for patient samples pre and post fulvestrant treatment.

	PATIENT 1		PATIENT 2		PATIENT 3	
	pre	post	pre	post	pre	post
Biopsy site	Breast primary tumour	Skin locoregional	Breast inoperable disease	Breast	Breast recurrence	Skin
ER status*	40%	15%	100%	90%	100%	90%
PgR status*	40%	0%	70%	0%	80%	90%
HER2 status**	3+amplified	3+ amplified	2+ non-amplified	2+ non-amplified	1+	0/1+
Ki67 status*	36%	50%	24%	40%	38%	13%
Treatments prior to fulvestrant	Letrozole, tamoxifen, exemestane		Letrozole		None	

* Percentage positive tumour cells for each marker

** Scored according to ASCO/CAP guidelines